Abstract: The invention relates to a binding member that binds the Extra Domain-A (ED-A) isoform of fibronectin for the treatment of lung cancer and lymphoma.

Abstract: The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease.

Abstract: The present invention provides antibodies that bind to the cat allergen, Fel d1, compositions comprising the antibodies, nucleic acids encoding the antibodies and methods of use of the antibodies. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to Fel d1. The antibodies of the invention are useful for binding to the Fel d1 allergen in vivo, thus preventing binding of the Fel d1 allergen to pre-formed IgE on the surface of mast cells or basophils. In doing so, the antibodies act to prevent the release of histamine and other inflammatory mediators from mast cells and/or basophils, thus ameliorating the untoward response to the cat allergen in sensitized individuals. The antibodies of the invention may also be useful for diagnostic purposes to determine if a patient is allergic to the Fel d1 cat allergen.

Abstract: The present invention provides an anti-human proBDNF monoclonal antibody, and uses thereof in pains. Specifically, the present invention provides uses of antibody polypeptide of tenth to 128th amino acid in a specific recognition pro-BDNF precursor protein structural domain, a nucleic acid sequence for coding the antibody polypeptide, a carrier comprising the nucleic acid sequence, a host comprising the carrier, a pharmaceutical composition comprising the antibody, and the antibody in the preparation of drugs used for alleviating and/or suppressing chronic pains.

Abstract: The invention describes methods of treating erosive polyarthritis comprising administering a TNF? antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF? antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.

Abstract: IL-18 participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool.

Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and IL-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.

Abstract: This invention relates to methods of screening for anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof, for potential use in treating or preventing PACAP-associated photophobia or light aversion, and therapeutic compositions containing and methods of using anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof.

Abstract: The present disclosure provides a method for enhancing or inducing an immune response and/or for inducing lysis of cancer cells and/or for treating cancer in a subject, the method comprising administering to the subject a compound that neutralizes BTN2A1 and/or that binds to BTN2A1 on the cells and induces death of the cells.

Abstract: Agents that specifically bind TIGIT are disclosed. The TIGIT-binding agents may include polypeptides, antibodies, and/or bispecific agents. Also disclosed are methods of using the agents for enhancing the immune response and/or treatment of diseases such as cancer.

Abstract: Disclosed are humanized RFB4 antibodies or antigen-binding fragments thereof. therapy of B-cell associated diseases, such as B-cell malignancies, autoimmune disease and immune dysfunction disease. Preferably, hRFB4 comprises the light and heavy chain RFB4 CDR sequences with human antibody FR and constant region sequences, along with heavy chain framework region (FR) amino acid residues Q1, F27, V48, A49, F68, R98, T117 and light chain residues L4, S22, K39, G100, V104, and K107. More preferably, the heavy and light chain variable region sequences of hRFB4 comprise SEQ ID NO:7 and SEQ ID NO:8, respectively. In certain embodiments, trogocytosis (antigen shaving) induced by hRFB4 plays a significant role in determining antibody efficacy and disease responsiveness for treatment of B-cell diseases, such as hematopoietic cancers, immune system dysfunction and/or autoimmune disease.

Abstract: The present invention provides a human PD-1 antibody, an antigen-binding fragment thereof, and medical use thereof, and further provides a chimeric antibody and humanized antibodies comprising a complementarity-determining region (CDR) of the antibody, a pharmaceutical composition comprising the human PD-1 antibody and the antigen-binding fragment thereof, and use of the antibody in preparing medicines for treating diseases or disorders.

Abstract: The invention provides antibodies that specifically bind to integrin ???6. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting ???6.

Abstract: Antibodies that bind to tumor associated antigen CD44 or to tumor associated antigen EphA2, are disclosed herein, as well as related compositions and methods of use. Methods of use encompass cancer therapies, diagnostics, and screening methods.

Abstract: The present invention provides isolated human monoclonal antibodies that bind to IFNAR-1 and that are capable of inhibiting the biological activity of Type I interferons. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting Type I interferon-mediated disorders using the antibodies of the invention, including methods for treating autoimmune disorders, transplant rejection or Graft Versus Host Disease using the antibodies of the invention.

Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for Fc?RIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.

Abstract: Compositions and methods are provided for treating diseases associated with CD20, including lymphomas, autoimmune diseases, and transplant rejections. Compositions include anti-CD20 antibodies capable of binding to a human CD20 antigen located on the surface of a human CD20-expressing cell, wherein the antibody has increased complement-dependent cell-mediated cytotoxicity (CDC) that is achieved by having at least one optimized CDR engineered within the variable region of the antibody. Compositions also include antigen-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-CD20 antibodies of the invention, or antigen-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier, and methods of use of these anti-CD20 antibodies.

Abstract: The present invention relates to methods of immunomodulation and treating patients having solid tumors with antibodies that specifically bind CD38.

Abstract: Pharmaceutical compositions comprising anti-CEACAM1 antibodies and kinase inhibitors are provided as well as methods for their use in treating cancer.

Abstract: Embodiments of the disclosure include methods and compositions related to chimeric antigen receptors (CAR) that target chondroitin sulfate proteoglycan-4 (CSPG4). T cells transduced with a CSPG4-specific CAR are effective for inhibition of particular cancer cells that express CSPG4. In certain embodiments, the cancer is melanoma, breast cancer, head and neck cancer, mesothelioma, glioblastoma, or renal cancer.

Abstract: The present disclosure relates to a method of inhibiting tumor growth. More specifically, the present disclosure relates to the use of monoclonal antibodies for targeting truncated O-glycans on glycoproteins to inhibit activation of pro-survival ceil signaling pathways, to inhibit tumor growth. For example, monoclonal antibody AR9.6 may be used to target truncated O-glycans on the MUC16 glycoprotein, thereby inhibiting the phosphatidyiinositol 3-kinase/Akt (Pi3K/Akt) signaling pathway.

Abstract: A method for purifying a polypeptide by ion exchange chromatography is described which involves changing the conductivity and/or pH of buffers in order to resolve a polypeptide of interest from one or more contaminants.

Abstract: The present invention relates to oncogenes or tumor suppressor genes, as well as other genes, involved in prostate cancer and their expression products, as well as derivatives and analogs thereof. Provided are therapeutic compositions and methods of detecting and treating cancer, including prostate and other related cancers. Also provided are methods of diagnosing and/or prognosing prostate cancer by determining the expression level of at least one prostate cancer-cell-specific gene, including, for example, the ERG gene or the LTF gene alone, or in combination with at least one of the AMACR gene and the DD3 gene.

Abstract: Methods for the cross-metathesis of polysaccharides with one or more olefin-terminated side chains and cross-metathesized products are described. In an exemplary embodiment, a method for the synthesis of cellulose ?-carboxyesters via olefin cross-metathesis with acrylates is described. Conditions of the reactions were relatively mild and the olefin-substituted polysaccharides and the appropriate acrylate partners appear to follow Grubbs rules as summarized herein. Additionally, a method of hydrogenation of the cross-metathesized product is described. The compounds and methods may be useful for waterborne coating applications, adhesives, lubricants, or any product in need of dispersion in an aqueous media.

Abstract: The presently disclosed and claimed inventive concept(s) relates to a polymer for enhancing drug performance and improving processability. Specifically, the polymer comprises hydroxypropyl methyl cellulose acetate succinate (HPMC-AS). On the HPMC-AS, the percentage of total succinoyl degree of substitution is less than 12% at C6-OH position and greater than 53% at C3-OH, and the percentage of total acetyl degree of substitution is greater than 32% at C6-OH position.

Abstract: The present invention relates to physically modified sago starch which exhibits an increased onset of gelatinization temperature and controlled viscosity development, yet retains significant hot and cold viscosity, the process of making such starch, and the use thereof. Such starches are useful in a variety of products, particularly as viscosifiers.

Abstract: Efficient cross-linking of hyaluronic acid (HA) is provided by a manufacturing process. In the process, HA is activated by an initial cross-linking in an aqueous solution. Unreacted cross-linking agent is removed from the activated HA. Cross-linking of the activated HA is finalized, without addition of any additional cross-linking agent, in a suspension of a liquid precipitating medium and the activated HA in precipitated form. The resulting cross-linked HA products exhibit high effective cross-linker ratio and other favorable properties, making the products useful as implants and in medical and cosmetic surgery.

Abstract: Provided is a sulfur-modified polychloroprene that generates a smaller amount of nitrosamine compounds during kneading or curing operation. A sulfur-modified polychloroprene, comprising functional groups having a structure represented by Chemical Formula I (in Chemical Formula I, R0 represents an alkyl group having 1 to 4 carbon atoms and x is an integer of 2 to 8) in an amount of 0.05 to 0.

Abstract: The present invention describes a process of preparing a catalyst for olefin polymerization comprising: (i) treating a magnesium metal with an organohalide along with an internal donor to obtain a reaction mixture having solid component (A); (ii) treating the reaction mixture having solid component (A) with an acyl halide to obtain a reaction mixture having solid component (B); and (iii) treating the reaction mixture having solid component (B) of step (ii) with a transition metal compound to obtain the catalyst. The present invention also relates to a process for preparation of a catalyst system from said catalyst and preparation of a polyolefins from the catalyst system.

Abstract: [Problem to be solved] There is provided a process for producing an olefin polymer that is capable of producing an olefin polymer having high heat resistance and high molecular weight with excellent catalytic activity. Solution to problem The process for producing an olefin polymer includes a step of polymerizing at least one olefin selected from ethylene and ?-olefins having 4 to 30 carbon atoms in the presence of an olefin polymerization catalyst containing a transition metal compound represented by the general formula [I], the olefin polymer including constituent units derived from ethylene and ?-olefins having 4 to 30 carbon atoms in a total amount between more than 50 mol % and not more than 100 mol %, [in the formula [I], R1, R3 and R5 to R16 are each independently a hydrogen atom, a hydrocarbon group or the like; R2 is a hydrocarbon group or the like; R4 is a hydrogen atom; M is a transition metal of Group IV; Q is a halogen atom or the like; and j is an integer of 1 to 4].

Abstract: A low viscosity polymer having a linear or branched backbone derived from farnesene monomers and at least one terminal-end functionalized with a hydroxyl group. This polymer may be further hydrogenated to reduce unsaturation and acrylated, such that it may be incorporated into a LOCA composition. The LOCA composition may be used in a laminated screen assembly, such as a touch screen, for electronic devices by adhering the LOCA composition between an optically transparent layer, such as a cover glass, and a display. The cured LOCA composition has a refractive index similar to the optically transparent layer. A method of making the low viscosity polymer for the LOCA composition includes anionically polymerizing farnesene monomers, quenching a living end of the polymer to provide the hydroxyl-terminated polymer; hydrogenating the hydroxyl-terminated polymer; and reacting the at least partially saturated hydroxyl-terminated polymer with at least one reagent to provide an acrylate terminated hydrogenated polymer.

Abstract: Provided is a method of preparing a vinyl chloride-based resin that includes preparing slurry through suspension polymerization by mixing a monomer, an oil soluble initiator, a dispersant, and an additive including an emulsifier, a water-soluble initiator, or a combination thereof, wherein the monomer includes vinyl chloride, an unsaturated carboxylic acid-based compound, and an ethylenic unsaturated compound that is copolymerizable therewith, and the emulsifier includes an anionic emulsifier, a non-ionic emulsifier, or a combination thereof.

Abstract: Disclosed are a resin blend, a copolymer, a pellet, a method of manufacturing a resin-molded article using the same, and a resin-molded article. The exemplary resin blend can be useful in providing a protective film for polarizing plates having excellent adhesive strength to a polarizer. Also, the resin blend can be useful in exhibiting excellent adhesive strength to the polarizer without performing an additional primer coating process on a surface(s) of the protective film for polarizing plate, thereby reducing production time and cost and improving productivity.

Abstract: Highly random acrylamide-acrylic acid copolymers are described. Ionic crosslinking of the highly random copolymers in dilute solution results in improved viscosity and gel strength compared to copolymers prepared by conventional methods. The ionically crosslinked copolymers are useful in enhanced oil recovery processes.

Abstract: A method of making acrylamide-acrylic acid copolymers in water-in-oil latices is described. The method results in a copolymer having randomly distributed carboxylate functionalities and is suitable for ionic crosslinking. The copolymers and their ionically crosslinked counterparts are useful for enhanced oil recovery processes.

Abstract: A moisture-curable composition includes a polymer preparable by free-radical copolymerization of monomers comprising at least one monomer A and at least one monomer B. Monomer(s) A comprise free-radically polymerizable hydrolyzable silane. Monomer(s) B include a divalent group selected from the group consisting of —(CF2O)a—, —(CF2CF2O)b—, —(CF2CF2CF2O)c—, —(CF2CF2CF2CF2O)d—, —(CF2CF(CF3)O)e—, and combinations thereof, wherein a, b, c, d, and e represent integers in the range of from 0 to 130, and wherein 1?<a+b+c+d+e?130. A composite article includes a layer of a composition on a substrate. The composition comprises a cross- linked reaction product of components including the moisture-curable composition. Methods of making the composite article are also disclosed.

Abstract: Polylactic acid-backbone graft and bottlebrush copolymers with low moisture vapor transmission rates are synthesized by polymerizing a lactide-functionalized hydrophobic macromonomer using ring-opening polymerization (ROP). In some embodiments of the present invention, the macromonomer is a lactide-functionalized hydrophobic polymer that may be synthesized by, for example, polymerizing a hydrophobic monomer (e.g., a fluorinated vinyl monomer such as 2,2,2-trifluroethyl methacrylate) capable of undergoing radical polymerization (e.g., styrenic, vinylic, acrylic, etc.) using a brominated lactide initiator via atom transfer radical polymerization (ATRP). The brominated lactide initiator may be 3-bromo-3,6-dimethyl-1,4-dioxane-2,5-dione prepared by, for example, reacting lactide with N-bromosuccinimide in the presence of benzoyl peroxide.

Abstract: A propylene-comonomer block copolymer may have a molecular weight distribution Mw/Mn of at least 1.7, a percentage of enthalpy measured between Ti and [Tm?18° C.] of at least 20% of the total enthalpy, and a ratio E1/Co of at least 0.80. The propylene-comonomer block copolymer may be produced by polymerizing propylene in the presence of at least one comonomer and a bridged metallocene catalyst. The bridged metallocene catalyst may include bridged fluorenyl, bridged indenyl metallocene, or any combination thereof. The propylene-comonomer block copolymer may be used as a heat seal layer for biaxially oriented multi-layer films.

Abstract: The present invention is directed to a functionalized elastomer having the formula (P-Bn)q-X where P is a polydiene segment, B is a styrenic monomer residue, n is the number of styrenic monomer residues, and Bn is a polystyrenic segment; X is a multifunctional terminator residue, and q is the number of (P-Bn) chains coupled to X; wherein for q=1, the weight percent of the functionalized elastomer is at least 90 percent by weight.

Abstract: Disclosed herein are highly active dilithio initiators prepared from high molecular weight dienes (C?6) and methods for the preparation of such compounds. These dilithio initiators result in greater control over polymer microstructure and provide useful polymers and oligomers with low vinyl incorporation.

Abstract: A liquid crystalline polyurethane elastomer is produced by reacting an isocyanate component, a high-molecular-weight polyol component and a mesogenic diol represented by formula (1), and having a crosslinking site that is introduced by a tri-functional or higher isocyanate in the isocyanate component and/or a high-molecular-weight polyol having a number average molecular weight of 400 or more and less than 7000 and having three or more hydroxy groups, in the high-molecular-weight polyol component, wherein the melting point of a mesogenic unit does not exist in a temperature range lying between the glass transition temperature (Tg) and the (liquid crystal phase)-to-(isotropic phase) transition temperature (Ti) of the polyurethane elastomer, and a liquid crystal is developed at a temperature between the Tg and the Ti. (In the formula, X represents an alkylene group having 3 to 20 carbon atoms; and Y represents a single bond, —N?N—, —CO—, —CO—O— or —CH?N—.

Abstract: Process for preparing rigid polyurethane or urethane-modified polyisocyanurate foams from polyisocyanates and polyfunctional isocyanate-reactive compounds in the presence of blowing agents wherein the polyfunctional isocyanate-reactive compounds comprise a polyether polyol having a hydroxyl number of between 50 and 650 mg KOH/g obtained by reacting a polyfunctional initiator first with ethylene oxide and subsequently with propylene oxide wherein the propoxylation degree is between 0.33 and 2 mole propylene oxide per active hydrogen atom in the initiator and wherein the molar ratio of ethylene oxide to propylene oxide in said polyether polyol is at least 2.

Abstract: A curable resin system comprising 1) an epoxy component having a polyglycidyl ether of a polyphenol having an epoxy equivalent weight of up to about 190; and 2) a hardener component comprising polyethylene tetraamine mixture; wherein the epoxy component has a viscosity of less than 9000 mPa·s at 25° C.

Abstract: (57) Abstract: The present invention concerns a process for the production of wind turbine structures. In the process, a stack of prepregs is located inside a vacuum bag. Each of the prepregs comprises a mixture of fibrous reinforcement and from 20% to 85 wt % of an epoxy resin of EEW 150 to 1500 and containing from 0.5 to 10 wt % of a curing agent. The curing agent comprises a urea curing agent and an imidazole curing agent, and is free of dicyandiamide. The epoxy resin is cured by application of an externally applied temperature in the range 70° C. to 110° C. for a period of from 4 to 8 hours.

Abstract: This disclosure provides a novel container, poly(neopentyl-2,5-furandicarboxylate) (PNPGF) and for methods of use thereof.

Abstract: The present invention provides new classes of phenol compounds, including those derived from tyrosol and analogues, useful as monomers for preparation of biocompatible polymers, and biocompatible polymers prepared from these monomeric phenol compounds, including novel biodegradable and/or bioresorbable polymers. These biocompatible polymers or polymer compositions with enhanced bioresorbabilty and processibility are useful in a variety of medical applications, such as in medical devices and controlled-release therapeutic formulations. The invention also provides methods for preparing these monomeric phenol compounds and biocompatible polymers.

Abstract: A method for synthesizing poly(butylene succinate) (PBS) having a weight average molecular weight (Mw) equal to or larger than 1.4×105. The method employs biogenic guanidine (BG) as the main catalyst and includes: a) adding succinic acid (SA), 1.4-butanediol (BDO), and biogenic guanidine to a reactor, heating the reactor to a temperature of between 180 and 200° C. and conducting the esterification between succinic acid and 1.4-butanediol for 2 to 3 hours under atmospheric pressure until all of the water is distilled or boiled off; and b) adding a first cocatalyst, a second cocatalyst, and a third cocatalyst to the reactor, adjusting the absolute pressure in the reactor to be between 0.5 and 3 torr, and polycondensing the mixture in the reactor at the temperature between 210 and 230° C. over 20 to 30 hours.

Abstract: A method for synthesizing poly(butylene adipate-co-terephthalate) by combination of melt and solid state polycondensation using an organic guanidine as a main catalyst. The ternary catalyst system includes a main catalyst, a first cocatalyst, and a second cocatalyst. The main catalyst is organic guanidine; the first cocatalyst is titanate ester or zirconate ester; and the second cocatalyst is metallic oxide. The method includes: 1) adding 1,4-butanediol (BDO), adipic acid (AA), terephthalic acid (TA), and a ternary catalyst system to a reaction still; conducting an oligo-polycondensation to yield a oligomer having the weight average molecular weight (Mw) of between 3.0×103 and 4.0×103; allowing the oligomer to perform a melt polycondensation (MP) to yield a prepolymer with medium Mw of between 1.5×104 and 3.0×104; and 2) crushing the solid prepolymer into granules of 30-40 meshes, and then allowing the granules to undergo solid state polycondensation to yield the final PBAT product.

Abstract: The disclosure relates to oxygen scavenging polymer compositions, methods of making the compositions, articles prepared from the compositions, and methods of making the articles. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: The present invention relates to copolycarbonates and a composition comprising the same. The copolycarbonate according to the present invention has a structure in which a specific siloxane compound is introduced in a main chain of the polycarbonate and thus, has characteristics of providing improved impact strength at low-temperature and improved YI (yellow index) simultaneously.